{"description":"Documents matching 'becaplermin'","count":5,"total_pages":1,"results":[{"title":"Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2002","type":"Proposed Rule","abstract":"This proposed rule would refine the resource-based practice expense relative value units and make several changes to Medicare Part B payment. The policy changes concern services and supplies incident to a physician's professional service; anesthesia base unit variations; recognition of CPT tracking codes; and nurse practitioners, physician assistants, and clinical nurse specialists performing screening sigmoidoscopies. We are proposing these refinements and changes to ensure that our payment systems are updated to reflect changes in medical practice and the relative value of services. We are soliciting comments on the proposed policy changes as well as comments on the payment policy for CPT modifier 62 that is used to report the work of co-surgeons. The Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000 modernizes the mammography screening benefit and authorizes payment under the physician fee schedule effective January 1, 2002; provides for biennial screening pelvic examinations for certain beneficiaries effective July 1, 2001; provides for annual glaucoma screenings for high-risk beneficiaries effective January 1, 2002; expands coverage for screening colonoscopies to all beneficiaries effective July 1, 2001; establishes coverage for medical nutrition therapy services for certain beneficiaries effective January 1, 2002; expands payment for telehealth services effective October 1, 2001; requires certain Indian Health Service providers to be paid for some services under the physician fee schedule effective July 1, 2001; and revises the payment for certain physician pathology services effective January 1, 2001. This proposed rule would conform our regulations to reflect the statutory provisions.","document_number":"01-18951","html_url":"https://www.federalregister.gov/documents/2001/08/02/01-18951/medicare-program-revisions-to-payment-policies-under-the-physician-fee-schedule-for-calendar-year","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2001-08-02/pdf/01-18951.pdf","public_inspection_pdf_url":null,"publication_date":"2001-08-02","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"Sildenafil citrate, 25 mg \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n XXX \n \n \n S0096 \n \n I \n Injection, itraconazole, 200 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n XXX \n \n \n S0156 \n \n I \n Exemestane, 25 mg \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n XXX \n \n \n S0157 \n \n I \n <span class=\"match\">Becaplermin</span> gel 1%, 0.5 gm \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n XXX \n \n \n S0220 \n \n I \n Medical conference by physic \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n XXX \n \n \n S0221 \n \n I \n Medical conference, 60 min \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n XXX \n \n \n S0601 \n "},{"title":"Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2001","type":"Rule","abstract":"This final rule with comment period makes several changes affecting Medicare Part B payment. The changes include: refinement of resource-based practice expense relative value units (RVUs); the geographic practice cost indices; resource-based malpractice RVUs; critical care RVUs; care plan oversight and physician certification and recertification for home health services; observation care codes; ocular photodynamic therapy and other ophthalmological treatments; electrical bioimpedance; antigen supply; and the implantation of ventricular assist devices. This rule also addresses the comments received on the May 3, 2000 interim final rule on the supplemental survey criteria and makes modifications to the criteria for data submitted in 2001. Based on public comments we are withdrawing our proposals related to the global period for insertion, removal, and replacement of pacemakers and cardioverter defibrillators and low intensity ultrasound. This final rule also discusses or clarifies the payment policy for incomplete medical direction, pulse oximetry services, outpatient therapy supervision, outpatient therapy caps, HCPCS \"G\" Codes, and the second 5-year refinement of work RVUs for services furnished beginning January 1, 2002. In addition, we are finalizing the calendar year (CY) 2000 interim physician work RVUs and are issuing interim RVUs for new and revised codes for CY 2001. We are making these changes to ensure that our payment systems are updated to reflect changes in medical practice and the relative value of services. This final rule also announces the CY 2001 Medicare physician fee schedule conversion factor under the Medicare Supplementary Medical Insurance (Part B) program as required by section 1848(d) of the Social Security Act. The 2001 Medicare physician fee schedule conversion factor is $38.2581.","document_number":"00-27833","html_url":"https://www.federalregister.gov/documents/2000/11/01/00-27833/medicare-program-revisions-to-payment-policies-under-the-physician-fee-schedule-for-calendar-year","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2000-11-01/pdf/00-27833.pdf","public_inspection_pdf_url":null,"publication_date":"2000-11-01","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Health Care Financing Administration","name":"Health Care Finance Administration","id":559,"url":"https://www.federalregister.gov/agencies/health-care-finance-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/559","parent_id":221,"slug":"health-care-finance-administration"}],"excerpts":"0.00 \n XXX \n \n \n S0098 \n \n D \n Injection, sodium ferric glu \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n XXX \n \n \n S0156 \n \n I \n Exemestane, 25 mg \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n XXX \n \n \n S0157 \n \n I \n <span class=\"match\">Becaplermin</span> gel 1%, 0.5 gm \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n XXX \n \n \n S0220 \n \n I \n Medical conference by physic \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n 0.00 \n XXX \n \n \n S0221 \n \n I \n Medical conference, 60 min \n 0.00"},{"title":"Determination of Regulatory Review Period for Purposes of Patent Extension; RegranexRegister and Becaplermin Concentrate","type":"Notice","abstract":"The Food and Drug Administration (FDA) has determined the regulatory review period for Regranex<Register> and Becaplermin Concentrate and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims those human biological products.","document_number":"99-5388","html_url":"https://www.federalregister.gov/documents/1999/03/04/99-5388/determination-of-regulatory-review-period-for-purposes-of-patent-extension-regranexregister-and","pdf_url":"https://www.govinfo.gov/content/pkg/FR-1999-03-04/pdf/99-5388.pdf","public_inspection_pdf_url":null,"publication_date":"1999-03-04","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"FDA recently approved for marketing the human biological products \nRegranex<Register> and <span class=\"match\">Becaplermin</span> Concentrate (<span class=\"match\">becaplermin</span>). \nRegranex<Register> is indicated for the treatment of lower extremity \ndiabetic neuropathic ulcers that extend into the subcutaneous tissue or \nbeyond and have an adequate blood supply. Subsequent to this approval, \nthe Patent and Trademark Office received a patent term restoration \napplication for Regranex<Register> and <span class=\"match\">Becaplermin</span> Concentrate (U.S. \nPatent No. 4,845,075) from ZymoGenetics, Inc., and the Patent and \nTrademark"},{"title":"Advice Concerning the Addition of Certain Pharmaceutical Products and Chemical Intermediates to the Pharmaceutical Appendix to the HTS","type":"Notice","abstract":"Following receipt on December 23, 1998, of a request from the United States Trade Representative (USTR), the Commission instituted investigation No. 332-402, Advice Concerning the Addition of Certain Pharmaceutical Products and Chemical Intermediates to the Pharmaceutical Appendix to the Harmonized Tariff Schedule of the United States, under section 332(g) of the Tariff Act of 1930 (19 U.S.C. 1332(g)). At the request of USTR, the Commission will provide: (1) A summary description of the products contained in the existing Pharmaceutical Appendix and the modifications to be made to that Appendix; (2) an explanation of the relationship of the various elements in the Appendix to the HTS; and (3) estimates of current U.S. imports, and where possible, U.S. exports of the products included in the Pharmaceutical Appendix and the proposed additions to the Appendix, based on product groupings as necessary. The Commission will submit its report to the USTR no later than April 1, 1999.","document_number":"99-1342","html_url":"https://www.federalregister.gov/documents/1999/01/21/99-1342/advice-concerning-the-addition-of-certain-pharmaceutical-products-and-chemical-intermediates-to-the","pdf_url":"https://www.govinfo.gov/content/pkg/FR-1999-01-21/pdf/99-1342.pdf","public_inspection_pdf_url":null,"publication_date":"1999-01-21","agencies":[{"raw_name":"INTERNATIONAL TRADE COMMISSION","name":"International Trade Commission","id":262,"url":"https://www.federalregister.gov/agencies/international-trade-commission","json_url":"https://www.federalregister.gov/api/v1/agencies/262","parent_id":null,"slug":"international-trade-commission"}],"excerpts":"123018-47-3\nAtizoram     135637-46-6\nAtliprofen     108912-17-0\nAtreleuton     154355-76-7\n\n[[Page 3311]]\n\n \nAviptadil      40077-57-4\nAvitriptan     151140-96-4\nAvorelin     140703-49-7\nAvotermin     182212-66-4\nBamaquimast     135779-82-7\nBasiliximab     179045-86-4\n<span class=\"match\">Becaplermin</span>     165101-51-9\nBectumomab     158318-63-9\nBelaperidone     156862-51-0\nBeloxepin     135928-30-2\nBepotastine     125602-71-3\nBibapcitide     153507-46-1\nBiricodar     159997-94-1\nBlonanserin     132810-10-7\nBrasofensine     171655-91-7\nBrinzolamide     138890-62-7\nCarafiban"},{"title":"Advisory Committee; Notice of Meeting","type":"Notice","abstract":null,"document_number":"97-15638","html_url":"https://www.federalregister.gov/documents/1997/06/16/97-15638/advisory-committee-notice-of-meeting","pdf_url":"https://www.govinfo.gov/content/pkg/FR-1997-06-16/pdf/97-15638.pdf","public_inspection_pdf_url":null,"publication_date":"1997-06-16","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"1-800-741-8138 (301-443-0572 in the \nWashington, DC area), code 12534. Please call the Information Line for \nup-to-date information on this meeting.\n\n    Agenda: On July 14, 1997, the committee will discuss biologic \nlicensing application (BLA) 96-1408, Regranex<Register> (<span class=\"match\">becaplermin</span> \n[PDGF-BB], Chiron Corp., in a carboxymethyl cellulose gel), OMJ \nPharmaceuticals, Inc., for treatment of chronic diabetic foot ulcers. \nOn July 15, 1997, the committee will participate in a general \nscientific discussion regarding the development of a possible future "}]}